NCT04681079 - Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

November 22, 2021

Study Completion Date

January 18, 2022

Conditions

COVID-19

Interventions

DRUG

albuterol sulfate (MDI)

albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer

DRUG

albuterol sulfate (nebulizer)

albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece

Trial Locations (1)

Theravance Biopharma Investigational Site, Kansas City